Last updated on November 2019

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Brief description of study

The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer.

Clinical Study Identifier: NCT04019327

Find a site near you

Start Over